Ryo Fujiwara, Takeshi Yuasa, Kenichi Kobayashi, Tetsuya Yoshida, Susumu Kageyama. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population. Expert review of anticancer therapy. 2023. 23. 5. 461-469
Koichiro Susa, Kenichi Kobayashi, Pierre Galichon, Takuya Matsumoto, Akitoshi Tamura, Ken Hiratsuka, Navin R. Gupta, Iman K. Yazdi, Joseph V. Bonventre, Ryuji Morizane. ATP/ADP biosensor organoids for drug nephrotoxicity assessment. Frontiers in Cell and Developmental Biology. 2023. 11
Susumu Kageyama, Tetsuya Yoshida, Kenichi Kobayashi, Akinori Wada, Masayuki Nagasawa, Shigehisa Kubota, Takuto Kusaba, Fumiyasu Jo, Shota Nakagawa, Kazuyoshi Johnin, et al. Prognostic nutritional index of early post-pembrolizumab therapy predicts long-term survival in patients with advanced urothelial carcinoma. Oncology letters. 2023. 25. 2. 49-49